Business Consulting · Launch & Brand Strategy
Launch & Post-Launch Diagnostic Intelligence
One integrated diagnostic. Four lenses. One story. We help pharma commercial teams turn fragmented sales, field, access, and account signals into a defensible answer on whether a launch is on track — and where to focus next.
"AI doesn't know your market. It doesn't know why Italy is behind and Spain is ahead. We do."
Trusted by commercial teams launching in specialty therapy areas across the EU
01 · The moment this is built for
Every launch reaches the point where leadership asks the hard question.
The product is live. The data exists — sales, field, access, invoice, account signals, owned by a dozen different teams. But nobody can give a clean answer on whether the launch is on track, or what to do next. That's the moment this diagnostic is built for.
01
02
03
Today
Fragmented
phamax brings
Connected & AI-ready
Outcome
Sales, field, access, invoice, and account data sit in different systems, owned by different teams. Every QBR is a debate about whose numbers are right.
Domain experts harmonise, govern, and reconcile the foundation — pharma-fluent from day one, built to be trusted before it reaches a leadership screen.
One defensible diagnostic
Leadership walks in with one agreed answer on where momentum is concentrated, what's holding it back, and where to invest next.
02 · What we deliver
One integrated diagnostic.Â
Four lenses. One story.
This is not a dashboard project and not a list of decision packs. It is a single diagnostic that examines a launch through four lenses commercial leadership already cares about — each designed to answer a question the team is already asking.
Lens 01
Commercial performance
Lens 02
Sales attainment
Before every leadership meeting, the team needs to answer one question quickly and consistently: is the launch on track? The diagnostic puts the full commercial picture in one view, from one reconciled source.
National numbers flatten the story. A strong quarter in one region can mask underperformance in three others. The diagnostic breaks the market down geographically — a map, not a national average.
Lens 03
Competitive position
Lens 04
Patient coverage
The question is rarely whether a competitor has an advantage. It's where, by how much, and whether the gap is closing or widening. External market data sits alongside internal sales.
Knowing where patients are — and whether the field has actually reached them — is the difference between a coverage strategy and a guess.
Same data the client already has. New foundation. New diagnostic. New conversation with leadership.
03 · How we get there
Connect. Examine. Decide.
A three-step approach that turns fragmented commercial signals into defensible decisions for the next phase of growth.
01
02
03
Connect
Build the foundation
Examine
Apply the diagnostic
Decide
Recommend the next move
Fragmented commercial, market, sales and field inputs harmonised into one decision-ready intelligence layer — pharma-fluent and governed.
The launch examined through four targeted diagnostic lenses, each designed to answer a specific question leadership is already asking.
Performance signals translated into territory-level recommendations — defensible decisions for the next phase of growth.
04 · Proof, from the field
Unlocking full market potential throughÂ
post-launch signals.
Rare Disease · Oncology · Germany